• CERo Therapeutics activated Seattle’s Fred Hutch Cancer Center for its Phase 1 CERTAIN-T blood cancer trial of CER-1236 on Oct. 26, 2026.
• Previously reported findings covered six patients; a June 2026 update showed no treatment-related severe adverse events during the safety assessment window.
• Preliminary investigator observations noted clinical improvement in two patients, but formal response assessments remain ongoing; no definitive safety or efficacy conclusions are possible.
• One patient with refractory acute myeloid leukemia subsequently underwent stem cell transplantation; the longer-term outcome remains under evaluation.
• The trial protocol now includes myelodysplastic syndromes and myelofibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260900PRIMZONEFULLFEED9852706) on October 26, 2026, and is solely responsible for the information contained therein.